4kq3: Difference between revisions

Line 1:

~~{{STRUCTURE_4kq3| PDB=4kq3 | SCENE= }}~~

==Crystal structure of Anti-IL-17A antibody CNTO3186==

===Crystal structure of Anti-IL-17A antibody CNTO3186===

~~{{ABSTRACT_PUBMED_24470236}}~~

== Structural highlights ==

<table><tr><td colspan='2'>[[4kq3]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4KQ3 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4KQ3 FirstGlance]. <br>

</td></tr><tr><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=MES:2-(N-MORPHOLINO)-ETHANESULFONIC+ACID'>MES</scene><br>

<tr><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=PCA:PYROGLUTAMIC+ACID'>PCA</scene></td></tr>

<tr><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4kq4|4kq4]]</td></tr>

<tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4kq3 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4kq3 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4kq3 RCSB], [http://www.ebi.ac.uk/pdbsum/4kq3 PDBsum]</span></td></tr>

<table>

== Publication Abstract from PubMed ==

Three Fab structures used as targets in the Antibody Modeling Assessment presented a challenge for modeling CDR-L3 due to deviations from the most typical canonical structure. In all three antibodies CDR-L3 has eight residues, which is one residue shorter than usual, and has a conformation that is rarely observed in crystal structures. We analyzed the sequence and structural determinants of this conformation and found that the "short" CDR-L3 is remarkably rigid and retains the conformation in the interactions with antigens and neighboring CDRs. Proteins 2014. (c) 2014 Wiley Periodicals, Inc.

~~==About this Structure==~~

Structural evidence for a constrained conformation of short CDR-L3 in antibodies.,Teplyakov A, Obmolova G, Malia TJ, Luo J, Gilliland GL Proteins. 2014 Jan 27. doi: 10.1002/prot.24522. PMID:24470236<ref>PMID:24470236</ref>

~~[[4kq3]] is~~ a ~~2 chain structure~~. ~~Full crystallographic information is available from [http~~:/~~/oca~~.~~weizmann~~.~~ac.il~~/~~oca-bin/ocashort?id=4KQ3 OCA].~~

==~~Reference~~==

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>

~~<ref group="xtra">PMID:024470236</ref>~~<references ~~group="xtra"~~/><~~references~~/>

</div>

== References ==

__TOC__

</StructureSection>

[[Category: Human]]

[[Category: Gilliland, G L.]]

[[Category: Malia, T.]]

Navigation menu

Page actions

Page actions

Personal tools

Navigation

Search

Tools

@@ Line 1: / Line 1: @@
-{{STRUCTURE_4kq3|  PDB=4kq3  |  SCENE=  }}
+==Crystal structure of Anti-IL-17A antibody CNTO3186==
-===Crystal structure of Anti-IL-17A antibody CNTO3186===
+<StructureSection load='4kq3' size='340' side='right' caption='[[4kq3]], [[Resolution|resolution]] 1.92&Aring;' scene=''>
-{{ABSTRACT_PUBMED_24470236}}
+== Structural highlights ==
+<table><tr><td colspan='2'>[[4kq3]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4KQ3 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4KQ3 FirstGlance]. <br>
+</td></tr><tr><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=MES:2-(N-MORPHOLINO)-ETHANESULFONIC+ACID'>MES</scene><br>
+<tr><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=PCA:PYROGLUTAMIC+ACID'>PCA</scene></td></tr>
+<tr><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4kq4|4kq4]]</td></tr>
+<tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4kq3 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4kq3 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4kq3 RCSB], [http://www.ebi.ac.uk/pdbsum/4kq3 PDBsum]</span></td></tr>
+<table>
+<div style="background-color:#fffaf0;">
+== Publication Abstract from PubMed ==
+Three Fab structures used as targets in the Antibody Modeling Assessment presented a challenge for modeling CDR-L3 due to deviations from the most typical canonical structure. In all three antibodies CDR-L3 has eight residues, which is one residue shorter than usual, and has a conformation that is rarely observed in crystal structures. We analyzed the sequence and structural determinants of this conformation and found that the "short" CDR-L3 is remarkably rigid and retains the conformation in the interactions with antigens and neighboring CDRs. Proteins 2014. (c) 2014 Wiley Periodicals, Inc.
-==About this Structure==
+Structural evidence for a constrained conformation of short CDR-L3 in antibodies.,Teplyakov A, Obmolova G, Malia TJ, Luo J, Gilliland GL Proteins. 2014 Jan 27. doi: 10.1002/prot.24522. PMID:24470236<ref>PMID:24470236</ref>
-[[4kq3]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4KQ3 OCA].
-==Reference==
+From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
-<ref group="xtra">PMID:024470236</ref><references group="xtra"/><references/>
+</div>
+== References ==
+<references/>
+__TOC__
+</StructureSection>
+[[Category: Human]]
 [[Category: Gilliland, G L.]]
 [[Category: Malia, T.]]